As such, there is a need for new ER-targeting therapies with increased anti-tumor activity to further delay disease progression and/or overcome resistance to the currently available hormonal therapies and ultimately prolong survival in women with ER+ advanced breast cancer. The gene discussed is ESR1; the disease is neoplasm.